1. Home
  2. LILA vs ANIP Comparison

LILA vs ANIP Comparison

Compare LILA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd.

LILA

Liberty Latin America Ltd.

HOLD

Current Price

$8.05

Market Cap

1.5B

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$75.20

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILA
ANIP
Founded
2017
2001
Country
Bermuda
United States
Employees
10000
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
LILA
ANIP
Price
$8.05
$75.20
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$9.75
$107.33
AVG Volume (30 Days)
367.1K
357.8K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.15
Revenue
N/A
$206,547,000.00
Revenue This Year
N/A
$44.10
Revenue Next Year
$7.70
$13.18
P/E Ratio
N/A
$36.17
Revenue Growth
N/A
2.47
52 Week Low
$4.25
$54.10
52 Week High
$9.04
$99.50

Technical Indicators

Market Signals
Indicator
LILA
ANIP
Relative Strength Index (RSI) 57.08 35.82
Support Level $7.90 $62.89
Resistance Level $8.25 $77.00
Average True Range (ATR) 0.39 2.65
MACD 0.01 -0.34
Stochastic Oscillator 53.74 2.16

Price Performance

Historical Comparison
LILA
ANIP

About LILA Liberty Latin America Ltd.

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: